Skip to NavigationSkip to content

Takeda's dengue vaccine proves efficacious in massive Phase 3 trial

Published on 30/01/19 at 11:42am

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing Phase 3 trial.

The tetravalent vaccine, which was found to be well tolerated, met its primary efficacy endpoint in a pivotal Phase 3 trial.

“We are very encouraged by the performance of our dengue vaccine candidate in the study. This brings us one step closer to helping the world tackle the massive burden of dengue,” said Dr Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda.

“We are excited to publish the data in a peer-reviewed journal as quickly as possible. In parallel, we are advancing the clinical development, commercial manufacturing, and stakeholder consultations to support a potential future global launch of the vaccine.”

The trial enrolled 20,000 healthy children and adolescents between the ages of four and 16, who were living in dengue-endemic areas.

The Japanese firm is also working on vaccines for other highly infectious including Zika, norovirus and polio.   

Louis Goss


Thanks for sharing the information. It is very useful for my future. keep sharing


Geometry Dash

Posts shared useful information and meaningful life, I'm glad to be reading this article and hope to soon learn the next article. thank you


Fleeing The Complex

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches